Literature DB >> 3396000

Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea.

W J Bodell1, K Tokuda, D B Ludlum.   

Abstract

The distribution of alkylated deoxynucleosides and bases has been determined in the DNA of a sensitive and a resistant human glioma-derived cell line exposed to therapeutic levels of [3H]N-(2-chloroethyl)-N-nitrosourea in vitro. The resistant cell line is 5-fold less sensitive to the cytotoxic effects of N-(2-chloroethyl)-N-nitrosourea and 8-fold less sensitive to sister chromatid exchange than the sensitive cell line. In comparison with the sensitive cells, DNA from the resistant cells contains much less of the cross-link, 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane. DNA from the resistant cells also contains significantly fewer minor base modifications. The decrease in 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane cross-link formation is probably explained by the higher level of O6-alkyltransferase in the resistant cell line. The lower levels of other DNA modifications could be explained by the presence of higher levels of other DNA repair activities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396000

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Mechanisms of resistance to alkylating agents.

Authors:  G Damia; M D'Incalci
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Repair of O6-G-alkyl-O6-G interstrand cross-links by human O6-alkylguanine-DNA alkyltransferase.

Authors:  Qingming Fang; Anne M Noronha; Sebastian P Murphy; Christopher J Wilds; Julie L Tubbs; John A Tainer; Goutam Chowdhury; F Peter Guengerich; Anthony E Pegg
Journal:  Biochemistry       Date:  2008-09-20       Impact factor: 3.162

3.  Evidence that covalent complex formation between BCNU-treated oligonucleotides and E. coli alkyltransferases requires the O6-alkylguanine function.

Authors:  P E Gonzaga; L Harris; G P Margison; T P Brent
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

4.  Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).

Authors:  William J Bodell; Alexander P Bodell; Donald D Giannini
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

Review 5.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.

Authors:  B C Liang
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

Review 8.  DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy.

Authors:  Julie L Tubbs; Anthony E Pegg; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.

Authors:  William J Bodell; Donald D Giannini; Saira Singh; Dennis Pietronigro; Victor A Levin
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

10.  Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts.

Authors:  A Malapetsa; J L Bramson; A J Noë; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.